68774-78-7

Basic information

• Product Name: 8-CHLORO-3-METHYL-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE
• Synonyms: 8-chloro-3-Methyl-[1;8-Chloro-3-methyltriazolo[4,3-a]pyrazine;8-CHLORO-3-METHYL-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE
• CAS NO: 68774-78-7
• Molecular Formula: C₆H₅ClN₄
• Molecular Weight: 168.58
• Mol File: 68774-78-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.59g/cm³
• Refractive Index: 1.743
• PKA: -0.33±0.30(Predicted)
• CAS DataBase Reference: 8-CHLORO-3-METHYL-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-CHLORO-3-METHYL-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE(68774-78-7)
• EPA Substance Registry System: 8-CHLORO-3-METHYL-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE(68774-78-7)

Safety Data

• Hazardous Substances Data: 68774-78-7(Hazardous Substances Data)

Usage

Uses

8-Chloro-3-methyl-1,2,4-triazolo[4,3-a]pyrazine is used as a reagent to synthesize derivatives of Formycin, a C-nucleoside antibiotic that inhibits the influenza A virus and is also known to replace adenosine during transcription.

InChI:InChI=1/C6H5ClN4/c1-4-9-10-6-5(7)8-2-3-11(4)6/h2-3H,1H3

Upstream product

• 1445-45-0 Trimethyl orthoacetate 
• 63286-28-2 2-chloro-3-hydrazinopyrazine 
• 78-39-7 Triethyl orthoacetate 

Relevant articles and documents

PYRIDAZINIUM COMPOUNDS FOR USE IN CONTROLLING UNWANTED PLANT GROWTH

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as herbicides.

Triazolo pyrazine compound containing heteroaryl substituted pyridazinone structure, and preparation method and applications thereof

The invention relates to a triazolo pyrazine compound containing a heteroaryl substituted pyridazinone structure, and pharmaceutically acceptable salts, hydrates, solvates, and a prodrug thereof, wherein the triazolo pyrazine compound containing a heteroa

BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).